Argenica Therapeutics Ltd (ASX: AGN) CEO Liz Dallimore speaks with Proactive from the ASX Small and Mid-Cap Conference March 2023. The company is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Its lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
